Paul Tudor Jones’s Aurinia Pharmaceuticals AUPH Stock Holding History

Paul Tudor Jones’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-51,568	Closed	-$764K	–	3537
2026 Q1	$764K	Sell	51,568 -11,570	-18%	-$169K	﹤0.01%	2546
2025 Q4	$1.01M	Sell	63,138 -2,826	-4%	-$40.1K	﹤0.01%	2270
2025 Q3	$729K	Buy	+65,964	New	+$720K	﹤0.01%	2478
2024 Q2	–	Sell	-14,954	Closed	-$74.9K	–	2309
2024 Q1	$74.9K	Buy	+14,954	New	+$101K	﹤0.01%	2107
2023 Q4	–	Sell	-13,533	Closed	-$105K	–	2356
2023 Q3	$105K	Buy	+13,533	New	+$132K	﹤0.01%	2148
2023 Q2	–	Sell	-105,952	Closed	-$1.16M	–	2416
2023 Q1	$1.16M	Buy	105,952 +64,113	+153%	+$565K	0.02%	1107
2022 Q4	$181K	Buy	+41,839	New	+$243K	﹤0.01%	2151
2022 Q3	–	Sell	-62,369	Closed	-$627K	–	2296
2022 Q2	$627K	Buy	+62,369	New	+$697K	0.02%	1143
2022 Q1	–	Sell	-31,176	Closed	-$713K	–	1992
2021 Q4	$713K	Buy	31,176 +15,176	+95%	+$360K	0.01%	1220
2021 Q3	$354K	Buy	+16,000	New	+$254K	0.01%	1918

Other funds holding AUPH

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Paul Tudor Jones's AUPH Position: Q2 2026 in Review

Paul Tudor Jones sold out of Aurinia Pharmaceuticals (AUPH) in Q2 2026, closing a stake of 51,568 shares — an estimated $764K sold.

Paul Tudor Jones first reported a position in AUPH in Q3 2021 and held it in 10 quarters. The position peaked at $1.16M in Q1 2023. 279 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

Paul Tudor Jones reported no remaining Aurinia Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Paul Tudor Jones sold 51,568 Aurinia Pharmaceuticals shares in Q2 2026, an estimated $764K.
Paul Tudor Jones first reported a position in Aurinia Pharmaceuticals in Q3 2021 and held it in 10 quarters.
Paul Tudor Jones's Aurinia Pharmaceuticals position peaked at $1.16M in Q1 2023.
279 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.